Japan Stomach Cancer Treatment Market Size, Share, and COVID-19 Impact Analysis, By Treatment Type (Standard Chemotherapy, Targeted Therapy, and Immunotherapy), By Route of Administration (Oral and Injectable), and Japan Stomach Cancer Treatment Market Insights, Industry Trend, Forecasts to 2035

Japan Stomach Cancer Treatment Market Insights Forecasts to 2035

• The Japan Stomach Cancer Treatment Market Size Was Estimated at USD 721.3 million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 6.64 % from 2025 to 2035
• The Japan Stomach Cancer Treatment Market Size is Expected to Reach USD 1462.8 million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Japan Stomach Cancer Treatment Market Size is anticipated to Reach USD 1462.8 Million by 2035, Growing at a CAGR of 6.64 % from 2025 to 2035. The stomach cancer treatment market in Japan is driven by various factors, including the rising incidence of stomach cancer, advancements in targeted therapies, rising awareness about early diagnosis, and government healthcare support.

Market Overview

Stomach cancer is also known as gastric cancer. The stomach cancer treatment market refers to the research, development, manufacturing, and distribution of products and services used to diagnose, treat, and manage stomach cancer. This market encompasses a variety of treatment methods, including immunotherapy, targeted therapy, chemotherapy, and surgery, in addition to supportive care products and diagnostic instruments. Stomach cancer develops by the formation of malignant (cancer) cells in the stomach lining. The high incidence of Helicobacter pylori infection in Japan presents lucrative growth prospects for the stomach cancer treatment market. Gastric pathogen Helicobacter pylori causes injury to the stomach lining and has the potential to cause cancer development. The rate of H. pylori seroprevalence was 37.6%–43.2% in 2022, according to an estimation by Baishideng Publishing Group. The market for stomach cancer treatments in Japan is expanding due to rising R&D expenditures, a spike in the approval of new treatments, and clinical studies. These initiatives are improving patient outcomes, increasing treatment alternatives, and increasing the availability of sophisticated and efficient therapeutic solutions. The rising preferences for personalized medicines are a key trend in this market.

Report Coverage

This research report categorizes the market for the Japan stomach cancer treatment market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan stomach cancer treatment market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan stomach cancer treatment market.

Driving Factors

Traditional Japanese diets rich in pickled, smoked, and salted foods, as well as preservatives like nitrates, are significantly associated with an elevated risk of stomach cancer. This contributes to the high incidence of the condition and increases the need for efficient treatment solutions. The rate of early diagnosis is also being boosted by increased government initiatives, such as public health campaigns that emphasize nutritional education, screening, and early detection. As a result, the need for novel and efficient therapies is growing, which is driving the market expansion. Additionally, advances in diagnostic technology play a crucial role in market growth.

Restraining Factors

Advanced treatments like immunotherapies and personalized medications are expensive, which restricts patient access and affordability, limiting the market expansion. Additionally, treatment efficacy is decreased by severe side effects and the development of resistance to chemotherapy or targeted therapy. This hinders market expansion due to discouraging patient adherence and limiting long-term success.

Market Segmentation

The Japan stomach cancer treatment market share is classified into treatment type and route of administration.   

• The targeted therapy segment held the dominant share of the market in 2024 and is expected to grow at a rapid CAGR during the forecast period.    

The Japan stomach cancer treatment market is segmented by treatment type into standard chemotherapy, targeted therapy, and immunotherapy. Among these, the targeted therapy segment held the dominant share of the market in 2024 and is expected to grow at a rapid CAGR during the forecast period. This is due to targeted therapy, which provides selective targeting of cancer cells and reduced harm to the surrounding normal tissue. Additionally, this particular method lowers related adverse effects and increases therapeutic efficacy.

• The injectable segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period.   

The Japan stomach cancer treatment market is segmented by route of administration into oral and injectable. Among these, the injectable segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This segmental growth is attributed to its rapid therapeutic action and effectiveness. Additionally, for individuals who have trouble taking oral drugs or who need a quick therapeutic response, this administration route is beneficial.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan stomach cancer treatment market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Ono Pharmaceutical
• Taiho Pharmaceutical
• Astellas Pharma
• Daiichi Sankyo
• Novartis Pharma K.K.
• Pfizer Japan Inc.
• Merck & Co., Inc.
• Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly Japan K.K.
• Bristol-Myers Squibb K.K.
• Celltrion Healthcare Japan K.K.
• Others

Recent Developments

• In February 2025, Chugai Pharma received MHLW approval for Tecentriq, an anti-PD-L1 antibody, expanding immunotherapy options for gastric cancer in Japan.

• In March 2024, Astellas Pharma received MHLW approval for VYLOY (zolbetuximab) to treat CLDN18.2-positive advanced gastric cancer in Japan.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan stomach cancer treatment market based on the below-mentioned segments:

Japan Stomach Cancer Treatment Market, By Treatment Type

• Standard Chemotherapy
• Targeted Therapy
• Immunotherapy

Japan Stomach Cancer Treatment Market, By Route of Administration

• Oral
• Injectable